Royalty Report: Drugs, Cancer, Disease – Collection: 4361

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • cell therapy
  • Diagnostic
  • Antibody
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4361

License Grant
Licensor hereby grants to Licensee an exclusive worldwide license, with the right to grant sublicensed, in all fields under the Licensed patents, to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Products.
License Property
Licensor is the owner by assignment of certain intellectual property relating to the treatment with opioid antagonists (such as naltrexone) and (met-enkephalin), alone or in combination with standard of care treatments, of a variety of diseases and conditions, including multiple sclerosis, cancer of the prostate, Lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, is treated in human patients by the administration, chronic herpes virus infections, chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic, A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC).  In particular, the inventions relate to methods and formulations for treatment of these conditions, including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to the intellectual property.

The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Licensed Patents
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346

Field of Use
The Licensee's most advanced clinical programs involve immunotherapy using Met-enkephalin (“MENK”) and low dose naltrexone (“LDN”). Both immunotherapies work by triggering opioid receptors on immune cells leading to an activation and expansion of various cells of the immune system.

In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.

IPSCIO Record ID: 344526

License Grant
Licensor, an individual in China, grants to Licensee an exclusive worldwide license, wi1th a right to grant sublicenses, in all fields under the Licensed Patents to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Processes.
License Property
The intellectual property includes patents titles
Met-enkephalin, its application in in treating leukemia and other blood cancers;
Met-enkephalin, its application in preparation of human and animal vaccine;
A nasal spray formulation containing Met enkephalin;
Low dose naltrexone, combined with MENK, its application in preparation of anticancer drug;
Compound met-enkephalin as a drug for colon cancer and pancreatic cancer; and,
Naltrexone as well as analogues being anticancer drug;
and, any other intellectual property of Licensor relating to !he following Multiple, Cancer of the prostate. Lymphoproliferative syndrome. including such diseases as malignant lymphoma. chronic lymphocytic leukemia, Hodgkins lymphoma, and non-Hodgkins lymphoma and all reissues or modification. reexaminations. or other related Chinese. PTC or U.S. patent filings directed to the same subject matter.

Licensed Product means any protocols, methods, therapies, or patient information.

Field of Use
The field of use is cancer and other related diseases.

IPSCIO Record ID: 243429

License Grant
This agreement is for the use of Herpes Simplex Virus Type 2 Antigens as Immunoprophylaxis or Immunotherapy to prevent or treat HSV Infections in Humans.

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

License Property
The research relates to the use of Herpes Simplex Virus Type 2 (HSV2) antigens as immunoprophylaxis or immunotherapy to prevent or treat HSV infections in humans.

Genital herpes is a sexually transmitted disease caused by the herpes simplex viruses HSV-1 or HSV-2, and in extreme cases, can appear in and about the eyes, esophagus, trachea, brain, and arms and legs.

Field of Use
The Field of Use means therapy that is administered to prevent or treat HSV2 infection.

IPSCIO Record ID: 390

License Grant
The Licensee of Vancouver, Canada, was granted the exclusive license for MTCH-24 and Viraplex® products worldwide outside of the United States.   We have developed two patented compounds MTCH-24(TM) and Viraplex(R). Both of these compounds show positive test results for treatment of a variety of enveloped viruses.
License Property
MTCH-24(TM) – Herpes I and II are enveloped viruses.  How MTCH-24 acts against enveloped viruses is not fully understood.  However, based on laboratory tests conducted for our company, MTCH-24 is believed to be effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudo rabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV).   It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals.

Viraplex(R), which is intended to be administered orally in capsule form as a prescription treatment for oro-facial and genital Herpes simplex virus infections, is in an advanced phase (the third of three phases) of clinical testing for safety and effectiveness in humans although such clinical testing has been suspended pending refinancing of the Company.
Viraplex(R) gave positive in vitro results against several forms of cancer, including breast, prostate and lung tumors.

The Company has developed over-the-counter products containing MTCH-24(tm) for treating the symptoms of herpes simplex virus infections of the lips, mouth or face known as cold sores and for the treatment of acne collectively, the 'OTC products'.

IPSCIO Record ID: 26783

License Grant
We acquired an interest in Chronix.
License Property
Chronix focuses upon the development of diagnostics for chronic diseases.  The collaborative research is an effort to develop intellectual property on potential new products for diagnosing and treating various chronic illnesses such as ME/CFS.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease that is difficult to diagnose and for which, at present, there is no cure.  People suffering from this illness experience, among other symptoms, a constant tiredness, recurring dull headaches, joint and muscle aches, a feeling of feverishness and chills low grade fever, depression, difficulty in concentrating on tasks, and tender lymph glands.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 46309

License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

IPSCIO Record ID: 280934

License Grant
This agreement is for development and commercialization of the clinical compound forodesine hydrochloride in markets across Europe, Asia and Australasia.

Licensor grants the Licensee of Bermuda an exclusive right and license in the Territory, with the right to sublicense, to Develop, make, have made, package and have packaged, use, promote, market, offer for sale, sell and import Licensed Products in the Field, under the Licensor Patents, Licensor Know-How and the Trademark.

Licensor grants during the Term of this Agreement a limited non-exclusive right to use the Licensor Logo on Promotional Literature in the Field in the Territory.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as PNP Inhibitors, including the compound known as __X-1777.

Licensed Products means all pharmaceutical preparations in all dosage strengths, formulations and methods of administration that contain the Compound as its active ingredient, alone or in combination with another active ingredient.

Trademark means the trademark Fodosine or such other trademark approved by the JDC for use in connection with the Licensed Products, but excluding the Secondary Marks.

B-cell Acute Lymphoblastic Leukemia/lymphoma or B-ALL means a disease in which certain cells of the B lymphocytes or B-cells are malignant, and have populated the bone marrow.

B-CLL means B-type chronic lymphocytic leukemia.

B-NHL means a Non-Hodgkin’s lymphoma in which the malignant cells have characteristics predominantly of the B lineage.

Field of Use
Field means the treatment of all Cancerous and/or Pre-Cancerous States in humans, specifically for the treatment of certain T-cell and B-cell mediated diseases in the area of oncology.
Fodosineâ„¢ is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in a number of clinical trials including a Phase IIa clinical trial in patients with T-cell leukemia.

IPSCIO Record ID: 243430

License Grant
This amendment addresses the sublicense consideration.

The original agreement is for the use of Herpes Simplex Virus Type 2 Antigens as Immunoprophylaxis or Immunotherapy to prevent or treat HSV Infections in Humans.

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

License Property
The research relates to the use of Herpes Simplex Virus Type 2 (HSV2) antigens as immunoprophylaxis or immunotherapy to prevent or treat HSV infections in humans.
Field of Use
The Field of Use means therapy that is administered to prevent or treat HSV2 infection.

IPSCIO Record ID: 1296

License Grant
The Company licensed rights to the use of MTCH-24(tm) against three viruses, the aids virus (hiv), Epstein-Barr virus and cytomegalovirus to a party for an ownership share.
License Property
MTCH-24 is an anti-microbial agent effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudorabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV).  It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals.  MTCH-24 (TM) has been shown to be effective in inhibiting and preventing the growth of Aspergillus on wheat and corn.

IPSCIO Record ID: 360156

License Grant
Swss Licensor provided Licensee with a royalty-bearing license (with the right to grant sublicenses through multiple tiers) to utilize patents and know-how to conduct research and to develop, make, use or offer for sale products developed from certain single chain fragment variable compounds known as DLX105 and DLX2751 owned by the Licensor.
License Property
DLX105 and DLX2751 means antibody therapies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies.
Field of Use
Field of use is for the treatment for the treatment of solid and hematological malignancies.

Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).

IPSCIO Record ID: 372435

License Grant
Licensor grants an exclusive, non-transferable license, with the right to grant sublicenses, under the Licensor Technology, to Exploit the Compounds and the Products in the Field in the Territory.

Licensor grants a non-exclusive license to use the Licensor Trademarks in connection with the Development and Commercialization of the Products.

License Property
Licensor has discovered and is developing a proprietary program that includes a Compound containing CD3 and CD19 specificities and is coded by Licensor as xx-011, with various potential human therapeutic uses.

Compound means xx-011, its derivatives and variants, including molecules that bind both Product Targets and are specifically claimed in Patents that specifically claim the amino acid sequence of xx-011; and any other DART derived from the DART Platform that binds both Product Targets.

DART means a dual affinity re-targeting molecule consisting of two binding arms, whereby the first arm binds a specificity conferred by an antibody variable region and the second arm binds a specificity conferred by a different antibody variable region.

DART Platform means Licensors proprietary platform for generating DARTs.

Indication means a discrete clinically recognized form of a disease, including DLBCL, chronic lymphocytic leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma.

Licensor Trademarks means the trademark DART, trademarks which incorporate the acronym DART, and related logos.

xx-011 is a humanized CD19 x CD3 bispecific DART protein.

Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations, including any method of delivery, containing a Compound alone or in combination with other active pharmaceutical ingredients, other than any active pharmaceutical ingredient that is owned or controlled by Licensor, including any Combination Product.

The patents include
—  Covalent Diabodies And Uses Thereof;
—  Covalent Diabodies And Uses;
—  Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life;
—  CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3; and,
—  Bi-Specific Diabodies That Are Capable Of Binding CD19 And CD3 And Uses Thereof.

Field of Use
The development and commercialization agreement is for MGD011, a product candidate that incorporates our proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell malignancies.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL).  These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Prognosis and treatment depend on type and stage of the cancer.

The Field means all uses, including the diagnosis, treatment or prevention of any disease in humans.  This agreement specifically discusses the development of xx-011 for Multiple 8-Cell Malignancies.

IPSCIO Record ID: 190857

License Grant
Licensor announced that the Centers for Medicare and Medicaid Services established a unique, product-specific billing code, J-code (J9034), for Bendeka. The J-code became effective on January 1, 2017. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, a chemotherapy drug used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
License Property
The original license agreement is for BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26485

License Grant
The Company entered into a licensing agreement with South Africa Licensee with respect to co-development of various RNA drugs, including Ampligen® . The licensing agreement provides Licensee with an exclusive manufacturing and marketing license for certain southern hemisphere countries (including certain countries in South America, Africa and Australia as well as the United Kingdom and Ireland (the licensed territory) .
License Property
Ampligen® is a our proprietary drug to treat diseases for which adequate treatment is not available. We seek the required regulatory approvals which will allow the progressive introduction of Ampligen® for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), HIV, Hepatitis C (“HCV”) and Hepatitis B (“HBV”) in the U.S., Canada, Europe and Japan. Ampligen® is currently in phase III clinical trials in the U.S. for use in treatment of ME/CFS and is in Phase IIb clinical trials in the U.S. for the treatment of newly emerged multi-drug resistant HIV, and for the induction of cell mediated immunity in HIV patients that are under control using potentially toxic drug cocktails.

Our proprietary drug technology Ampligen® utilizes specially configured ribonucleic acid (“RNA”) and is protected by more than 350 patents worldwide with over 80 additional patent applications  pending to provide further proprietary protection in various international markets. Certain patents apply to the use of Ampligen® alone and certain patents apply to the use of Ampligen® in combination with certain other drugs. Some composition of matter patents pertain to other new medications which have a similar mechanism of action. The main U.S. ME/CFS treatment patent (#6130206) expires January 23, 2015. Our main patents covering HIV treatment (#4795744,#4820696, #5063209, and #5091374) expire on August 26, 2006, September 30, 2008, August 10, 2010, respectively; Hepatitis treatment coverage is conveyed by U.S. patent #5593973 which expires on October 15, 2014. The U.S. Ampligen® Trademark (#1,515,099) expires on December 6, 2008 and can be renewed thereafter for an additional 10 years. The U.S. FDA has granted us “orphan drug status” for our nucleic acid-derived therapeutics for ME/CFS, HIV, and renal cell carcinoma and malignant melanoma. Orphan drug status grants the Company protection against competition for a period of seven years following FDA approval, as well as certain federal tax incentives, and other regulatory benefits.

IPSCIO Record ID: 7354

License Grant
This Binding Letter of Intent is entered into by and between the Licensor and the Licensee. The Parties wish to enter into an licensing transaction whereby the Licensee would receive a worldwide license to the Assets in exchange for the issuance of shares of common stock.
Field of Use
The Licensee wishes to license certain assets and intellectual property rights from the Licensor related to Pro-Cyclovir codrug and its use for the treatment of Herpes Labialis caused by HSV-1.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. It causes small, painful blisters commonly called cold sores or fever blisters. Oral herpes is also called herpes labialis.

IPSCIO Record ID: 204323

License Grant
Korean Licensor grants an exclusive license, with the right to sublicense, under all Licensor Patent Rights and Know-How, including, without limitation, Licensors rights in Licensors Inventions, to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Program Products in the Licenses Territory in the Anti-HBV Field.
License Property
The Program Product means any pharmaceutical formulation containing a Compound for administration to humans to treat chronic Hepatitis B Virus or HBV infection.

Hepatitis B virus, or HBV, infection is a growing global health problem that can cause both acute and chronic viral infections.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.

IP relates to potential commercialization LB80380 (ANA380), a Phase II nucleotide analog for the treatment of chronic hepatitis B virus infection.

Field of Use
LB80380 (ANA380) is a nucleotide analog currently in Phase II clinical trials for the treatment of chronic HBV infection. The compound has exhibited activity in vitro against both HBV typically found in untreated patients and also HBV variants that demonstrate resistance to treatment with the nucleotide analog lamivudine, which is a currently commercialized therapy for HBV. Preclinical studies have demonstrated significant activity against HBV, low potential for drug interactions and good tolerability in a range of preclinical toxicology studies. Based on clinical trials to date, LB80380 (ANA380) appears to offer the potential for once daily dosing.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.